Related Experiment Video
Updated: May 2, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
A new recombinant hybrid polypeptide and its immunologic adjuvant activity for inactivated infectious bursal disease
Mei-hong Cai1, Feng Zhu, Hao-chen Wu
1School of Food and Biology Engineering, Jiangsu University, Zhenjiang, 212013, Jiangsu, China, caimeihong@gmail.com.
Both bursin (Lys-His-Gly-NH2) and Gagnon's peptides (Lys-Asn-Pro-Tyr) can induce B-cell differentiation. However, it is unclear whether a recombinant hybrid polypeptide consisting of a tandem array of 14 copies of bursin and two copies of Gagnon's peptide can induce the proliferative activity of lymphocytes. Here, this recombinant hybrid polypeptide was expressed in Escherichia coli and purified by SDS-PAGE. Various assays showed that it not only promoted B-lymphocyte proliferation in vitro but also increased the titers of antibodies directed against infectious bursal disease virus fourfold in the sera of chickens vaccinated with the inactivated infectious bursal disease virus vaccine. The recombinant hybrid polypeptide also reduced the pathological lesions in the bursa of Fabricius caused by infectious bursal disease virus BC6/85. Our results show that this recombinant hybrid polypeptide may be a promising immune adjuvant.
Both bursin (Lys-His-Gly-NH2) and Gagnon's peptides (Lys-Asn-Pro-Tyr) can induce B-cell differentiation. However, it is unclear whether a recombinant hybrid polypeptide consisting of a tandem array of 14 copies of bursin and two copies of Gagnon's peptide can induce the proliferative activity of lymphocytes. Here, this recombinant hybrid polypeptide was expressed in Escherichia coli and purified by SDS-PAGE. Various assays showed that it not only promoted B-lymphocyte proliferation in vitro but also increased the titers of antibodies directed against infectious bursal disease virus fourfold in the sera of chickens vaccinated with the inactivated infectious bursal disease virus vaccine. The recombinant hybrid polypeptide also reduced the pathological lesions in the bursa of Fabricius caused by infectious bursal disease virus BC6/85. Our results show that this recombinant hybrid polypeptide may be a promising immune adjuvant.
More Related Videos
13:36Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
10:11Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
Published on: January 31, 2018
Related Concept Videos
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Vaccinations